Status:
NOT_YET_RECRUITING
An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on Lung Cancer Patients
Lead Sponsor:
The First Affiliated Hospital of Guangzhou Medical University
Conditions:
LUNG CANCER
Eligibility:
All Genders
18+ years
Brief Summary
To evaluate the impact of the 23-valent pneumonia vaccine on the incidence of pulmonary infection and survival in lung cancer patients, and to explore its preventive effect and safety in the lung canc...
Eligibility Criteria
Inclusion
- Male or female patients \>=18 years of age;
- Histological diagnosis of NSCLC, including both non-small cell lung cancer and small cell lung cancer, regardless of whether they are in the early, locally advanced stage or advanced stage, and regardless of whether they have received surgery, radiotherapy, chemotherapy or other treatments;
- Never received pneumococcal vaccine
Exclusion
- Patients having other factors that preventing researchers from enrollment them.
Key Trial Info
Start Date :
September 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2030
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT07142057
Start Date
September 1 2025
End Date
September 1 2030
Last Update
August 26 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.